This situation has been improved with the availability of idarucizumab, the monoclonal antibody for reversal of dabigatran.1 We hope this antidote will produce clinically meaningful hemostasis following administration, but unfortunately, the best data available come to us from a single-arm trial. A specific antidote was not available, nor was a factor replacement strategy clearly efficacious. The introduction and initial popularity of dabigatran caught us lacking, with no useful options for managing hemorrhage. One-hour Acute Myocardial Infarction Rule-Out Not Ready for Prime TimeĮxplore This Issue ACEP Now: Vol 38 – No 04 – April 2019Į ver since the release of direct-acting oral anticoagulants, emergency physicians have been tasked with managing their associated complications.
0 kommentar(er)
